Oncolytic virotherapy of gynecologic malignancies

Gynecologic Oncology

Volumn 120, Issue 2, 2011, Pages 302-310

  Hartkopf, Andreas D ^a   Fehm, Tanja ^a   Wallwiener, Diethelm ^a   Lauer, Ulrich ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Cervical cancer; Gynecologic malignancies; Oncolytic virus; Ovarian cancer; Replication selective; Virotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSINE DEAMINASE; CYTOTOXIC AGENT; EPIRUBICIN; FLUCYTOSINE; FLUOROURACIL; G 207; GANCICLOVIR; GEMCITABINE; H 101; INTERLEUKIN 12; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC MEASLES VACCINE VIRUS; ONCOLYTIC MUMPS VIRUS; ONCOLYTIC REOVIRUS; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; ONYX 015; REOLYSIN; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ASCITES; BREAST CARCINOMA; CANCER RADIOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ENDOMETRIUM CANCER; FLU LIKE SYNDROME; GENE DELIVERY SYSTEM; GENETIC ENGINEERING; GLIOBLASTOMA; GYNECOLOGIC CANCER; HUMAN; IN VIVO STUDY; IONIZING RADIATION; MALIGNANT ASCITES; MEDLINE; MONITORING; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SUICIDE GENE THERAPY; TRANSGENE; UTERINE CERVIX CANCER; VAGINA BLEEDING; VIRUS REPLICATION;

FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 79251593962     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.10.031     Document Type: Review

References (136)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. V. Masciullo, G. Amadio, D. Lo Russo, I. Raimondo, A. Giordano, and G. Scambia Controversies in the management of endometrial cancer Obstet Gynecol Int 2010 2010 638165
3. NIH consensus conference Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer Jama 273 1995 491 497
4. A.Z. Bluming, and J.L. Ziegler Regression of Burkitt's lymphoma in association with measles infection Lancet 2 1971 105 106
5. A.M. Taqi, M.B. Abdurrahman, A.M. Yakubu, and A.F. Fleming Regression of Hodgkin's disease after measles Lancet 1 1981 1112
6. N.G. DePace Sulla Scomparsa di un enorme cancro begetante del callo dell'utero senza cura chirurgica Ginecolgia 9 1912 82
7. R.J. Huebner, W.P. Rowe, W.E. Schatten, R.R. Smith, and L.B. Thomas Studies on the use of viruses in the treatment of carcinoma of the cervix Cancer 9 1956 1211 1218
8. W.A. Cassel, and R.E. Garrett Newcastle disease virus as an antineoplastic agent Cancer 18 1965 863 868
9. Y. Shimizu, K. Hasumi, Y. Okudaira, K. Yamanishi, and M. Takahashi Immunotherapy of advanced gynecologic cancer patients utilizing mumps virus Cancer Detect Prev 12 1988 487 495
10. T.C. Liu, E. Galanis, and D. Kirn Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress Nat Clin Pract Oncol 4 2007 101 117
11. D. Kirn, R.L. Martuza, and J. Zwiebel Replication-selective virotherapy for cancer: biological principles, risk management and future directions Nat Med 7 2001 781 787
12. C.M. Vollmer, A. Ribas, L.H. Butterfield, V.B. Dissette, K.J. Andrews, and F.C. Eilber p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma Cancer Res 59 1999 4369 4374
13. M.J. Clemens PKR-a protein kinase regulated by double-stranded RNA Int J Biochem Cell Biol 29 1997 945 949
14. M.V. Davies, H.W. Chang, B.L. Jacobs, and R.J. Kaufman The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms J Virol 67 1993 1688 1692
15. F. Imani, and B.L. Jacobs Inhibitory activity for the interferon-induced protein kinase is associated with the reovirus serotype 1 sigma 3 protein Proc Natl Acad Sci USA 85 1988 7887 7891
16. Y. Lu, M. Wambach, M.G. Katze, and R.M. Krug Binding of the influenza virus NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the elF-2 translation initiation factor Virology 214 1995 222 228
17. G.D. Ghadge, P. Malhotra, M.R. Furtado, R. Dhar, and B. Thimmapaya In vitro analysis of virus-associated RNA I (VAI RNA): inhibition of the double-stranded RNA-activated protein kinase PKR by VAI RNA mutants correlates with the in vivo phenotype and the structural integrity of the central domain J Virol 68 1994 4137 4151
18. D.F. Stojdl, B. Lichty, S. Knowles, R. Marius, H. Atkins, and N. Sonenberg Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus Nat Med 6 2000 821 825
19. O. Haus The genes of interferons and interferon-related factors: localization and relationships with chromosome aberrations in cancer Arch Immunol Ther Exp (Warsz) 48 2000 95 100
20. R.M. Lorence, P.A. Rood, and K.W. Kelley Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity J Natl Cancer Inst 80 1988 1305 1312
21. G.R. Peplinski, A.K. Tsung, M.J. Casey, J.B. Meko, T.N. Fredrickson, and R.M. Buller In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1beta Cancer J Sci Am 2 1996 21 27
22. J. Rommelaere, and J.J. Cornelis Antineoplastic activity of parvoviruses J Virol Methods 33 1991 233 251
23. D. Grote, S.J. Russell, T.I. Cornu, R. Cattaneo, R. Vile, and G.A. Poland Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice Blood 97 2001 3746 3754
24. M.C. Coffey, J.E. Strong, P.A. Forsyth, and P.W. Lee Reovirus therapy of tumors with activated Ras pathway Science 282 1998 1332 1334
25. K. Hasegawa, L. Pham, M.K. O'Connor, M.J. Federspiel, S.J. Russell, and K.W. Peng Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter Clin Cancer Res 12 2006 1868 1875
26. M. Hingorani, G. Spitzweg, G. Vassaux, K. Newbold, A. Melcher, and H. Pandha The biology of the sodium iodide symporter and its potential for targeted gene delivery Curr Cancer Drug Targets 10 2010 242 267
27. E. Galanis, L.C. Hartmann, W.A. Cliby, H.J. Long, P.P. Peethambaram, and B.A. Barrette Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer Cancer Res 70 2010 875 882
28. T. Ichikawa, and E.A. Chiocca Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector Cancer Res 61 2001 5336 5339
29. G.R. Harsh, T.S. Deisboeck, D.N. Louis, J. Hilton, M. Colvin, and J.S. Silver Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study J Neurosurg 92 2000 804 811
30. R. Strauss, and A. Lieber Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo Mol Ther 11 2009 513 522
31. S. Lal, U.M. Lauer, D. Niethammer, J.F. Beck, and P.G. Schlegel Suicide genes: past, present and future perspectives Immunol Today 21 2000 48 54
32. J.A. Bridgewater, C.J. Springer, R.J. Knox, N.P. Minton, N.P. Michael, and M.K. Collins Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954 Eur J Cancer 31A 1995 2362 2370
33. E. Garcia-Aragoncillo, and R. Hernandez-Alcoceba Design of virotherapy for effective tumor treatment Curr Opin Mol Ther 12 2010 403 411
34. K.W. Peng, C.J. TenEyck, E. Galanis, K.R. Kalli, L.C. Hartmann, and S.J. Russell Intraperitoneal therapy of ovarian cancer using an engineered measles virus Cancer Res 62 2002 4656 4662
35. K. Hirasawa, S.G. Nishikawa, K.L. Norman, T. Alain, A. Kossakowska, and P.W. Lee Oncolytic reovirus against ovarian and colon cancer Cancer Res 62 2002 1696 1701
36. R. Lal, D. Harris, S. Postel-Vinay, and J. de Bono Reovirus: rationale and clinical trial update Curr Opin Mol Ther 11 2009 532 539
37. D.E. Cohn, G. Nuovo, M.C. Coffey, D. O'Malley, M.A. Villalona-Calero, and M.R. Grever Phase I/II trial of reovirus serotype 3-Dearing strain in patients with recurrent ovarian cancer J Clin Oncol 28 2010 15s (abstr TPS253)
38. M.A. Phelps, D.E. Cohn, D.M. O'Malley, L. Wei, D. Wilkins, and A. Campbell Reovirus replication in ovarian and peritoneal tumors after intravenous administration Proceedings of the 101th Annual Meeting of the American Association for Cancer Research 2010 (abstr 2594)
39. R.E. Dorig, A. Marcil, A. Chopra, and C.D. Richardson The human CD46 molecule is a receptor for measles virus (Edmonston strain) Cell 75 1993 295 305
40. L. Bjorge, J. Hakulinen, T. Wahlstrom, R. Matre, and S. Meri Complement-regulatory proteins in ovarian malignancies Int J Cancer 70 1997 14 25
41. B.D. Anderson, T. Nakamura, S.J. Russell, and K.W. Peng High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus Cancer Res 64 2004 4919 4926
42. M.R. Hilleman Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications Vaccine 20 2001 651 665
43. F.T. Cutts, and L.E. Markowitz Successes and failures in measles control J Infect Dis 170 Suppl 1 1994 S32 S41
44. K.W. Peng, S. Facteau, T. Wegman, D. O'Kane, and S.J. Russell Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides Nat Med 8 2002 527 531
45. K. Hasegawa, T. Nakamura, M. Harvey, Y. Ikeda, A. Oberg, and M. Figini The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer Clin Cancer Res 12 2006 6170 6178
46. M. Wu, W. Gunning, and M. Ratnam Expression of folate receptor type alpha in relation to cell type, malignancy, and differentation in ovary, uterus, and cervix Cancer Epidemiol Biomarkers Prev 8 1999 775 782
47. G.W. Milton, and M.M. Brown The limited role of attenuated smallpox virus in the management of advanced malignant melanoma Aust N Z J Surg 35 1966 286 290
48. I. Hunter-Craig, K.A. Newton, G. Westbury, and B.W. Lacey Use of vaccinia virus in the treatment of metastatic malignant melanoma Br Med J 2 1970 512 515
49. S. Arakawa Jr., G. Hamami, K. Umezu, S. Kamidono, J. Ishigami, and S. Arakawa Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma. Report on two cases J Cancer Res Clin Oncol 113 1987 95 98
50. L.G. Gomella, M.J. Mastrangelo, P.A. McCue, H.J. Maguire, S.G. Mulholland, and E.C. Lattime Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer J Urol 166 2001 1291 1295
51. A. Kawa, and S. Arakawa The effect of attenuated vaccinia virus AS strain on multiple myeloma; a case report Jpn J Exp Med 57 1987 79 81
52. A.M. Crompton, and D.H. Kirn From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development Curr Cancer Drug Targets 7 2007 133 139
53. J.A. McCart, J.M. Ward, J. Lee, Y. Hu, H.R. Alexander, and S.K. Libutti Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes Cancer Res 61 2001 8751 8757
54. M. Puhlmann, C.K. Brown, M. Gnant, J. Huang, S.K. Libutti, and H.R. Alexander Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant Cancer Gene Ther 7 2000 66 73
55. C.F. Hung, Y.C. Tsai, L. He, G. Coukos, I. Fodor, and L. Qin Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice Gene Ther 14 2007 20 29
56. S. Chalikonda, M.H. Kivlen, M.E. O'Malley, X.D. Eric Dong, J.A. McCart, and M.C. Gorry Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene Cancer Gene Ther 15 2008 115 125
57. D.F. Stojdl, B.D. Lichty, B.R. tenOever, J.M. Paterson, A.T. Power, and S. Knowles VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents Cancer Cell 4 2003 263 275
58. J.R. Bischoff, D.H. Kirn, A. Williams, C. Heise, S. Horn, and M. Muna An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 274 1996 373 376
59. F.D. Goodrum, and D.A. Ornelles p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection J Virol 72 1998 9479 9490
60. A.S. Turnell, R.J. Grand, and P.H. Gallimore The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status J Virol 73 1999 2074 2083
61. J. Nemunaitis, F. Khuri, I. Ganly, J. Arseneau, M. Posner, and E. Vokes Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer J Clin Oncol 19 2001 289 298
62. I. Ganly, D. Kirn, G. Eckhardt, G.I. Rodriguez, D.S. Soutar, and R. Otto A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 2000 798 806
63. G.J. Bauerschmitz, J.T. Lam, A. Kanerva, K. Suzuki, D.M. Nettelbeck, and I. Dmitriev Treatment of ovarian cancer with a tropism modified oncolytic adenovirus Cancer Res 62 2002 1266 1270
64. P.A. Vasey, L.N. Shulman, S. Campos, J. Davis, M. Gore, and S. Johnston Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer J Clin Oncol 20 2002 1562 1569
65. Z.Y. Yuan, L. Zhang, S. Li, X.Z. Qian, and Z.Z. Guan Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer Ai Zheng 22 2003 310 313
66. H.L. Liu, and J. Chen Oncolytic virus as an agent for the treatment of malignant ascites Cancer Biother Radiopharm 24 2009 99 102
67. A. Hemminki, N. Belousova, K.R. Zinn, B. Liu, M. Wang, and T.R. Chaudhuri An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression Mol Ther 4 2001 223 231
68. S.C. Stevenson, M. Rollence, B. White, L. Weaver, and A. McClelland Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain J Virol 69 1995 2850 2857
69. A. Kanerva, K.R. Zinn, T.R. Chaudhuri, J.T. Lam, K. Suzuki, and T.G. Uil Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus Mol Ther 8 2003 449 458
70. C.J. Sherr Cancer cell cycles Science 274 1996 1672 1677
71. D.T. Curiel, M. Preuss, M. Wang, K.J. Kimball, M.N. Barnes, and W. Wan A phase I study of the infectivity enhanced CRAd Ad5-delta24RGD for recurrent gynecologic cancer J Clin Oncol 28 2010 15s (abstr 5107)
72. A. Kanerva, K.R. Zinn, K.W. Peng, T. Ranki, L. Kangasniemi, and T.R. Chaudhuri Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus Gene Ther 12 2005 87 94
73. M. Raki, T. Hakkarainen, G.J. Bauerschmitz, M. Sarkioja, R.A. Desmond, and A. Kanerva Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus Gene Ther 14 2007 1380 1388
74. G.J. Bauerschmitz, K. Guse, A. Kanerva, A. Menzel, I. Herrmann, and R.A. Desmond Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells Mol Ther 14 2006 164 174
75. K.S. Dingwell, and D.C. Johnson The herpes simplex virus gE-gI complex facilitates cell-to-cell spread and binds to components of cell junctions J Virol 72 1998 8933 8942
76. E. De Clercq Antiviral drugs in current clinical use J Clin Virol 30 2004 115 133
77. B. Roizman, D.M. Knipe, and R.J. Whitley Herpes simplex viruses B.N. Fields, D.M. Knipe, P.M. Howely, D.E. Griffin, Herpes simplex viruses 5th ed. 2007 Lippincott Williams & Wilkins 2501 2847 Philadelphia
78. Y. Shen, and J. Nemunaitis Herpes simplex virus 1 (HSV-1) for cancer treatment Cancer Gene Ther 13 2006 975 992
79. K.L. Mossman, and J.R. Smiley Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication J Virol 76 2002 1995 1998
80. E.A. McKie, A.R. MacLean, A.D. Lewis, G. Cruickshank, R. Rampling, and S.C. Barnett Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours-evaluation of a potentially effective clinical therapy Br J Cancer 74 1996 745 752
81. J.C. Kucharczuk, B. Randazzo, M.Y. Chang, K.M. Amin, A.A. Elshami, and D.H. Sterman Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma Cancer Res 57 1997 466 471
82. B.P. Randazzo, M.G. Bhat, S. Kesari, N.W. Fraser, and S.M. Brown Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant J Invest Dermatol 108 1997 933 937
83. S. Harrow, V. Papanastassiou, J. Harland, R. Mabbs, R. Petty, and M. Fraser HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival Gene Ther 11 2004 1648 1658
84. F. Benencia, M.C. Courreges, J.R. Conejo-Garcia, A. Mohamed-Hadley, L. Zhang, and R.J. Buckanovich HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer Mol Ther 12 2005 789 802
85. T. Mineta, S.D. Rabkin, and R.L. Martuza Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant Cancer Res 54 1994 3963 3966
86. J.M. Markert, P.G. Liechty, W. Wang, S. Gaston, E. Braz, and M. Karrasch Phase Ib trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM Mol Ther 17 2009 199 207
87. J.M. Markert, M.D. Medlock, S.D. Rabkin, G.Y. Gillespie, T. Todo, and W.D. Hunter Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial Gene Ther 7 2000 867 874
88. G. Coukos, A. Makrigiannakis, S. Montas, L.R. Kaiser, T. Toyozumi, and I. Benjamin Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy Cancer Gene Ther 7 2000 275 283
89. X. Fu, L. Tao, and X. Zhang An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer Cancer Gene Ther 14 2007 480 487
90. K.F. Hsu, C.L. Wu, S.C. Huang, J.L. Hsieh, Y.S. Huang, and Y.F. Chen Conditionally replicating E1B-deleted adenovirus driven by the squamous cell carcinoma antigen 2 promoter for uterine cervical cancer therapy Cancer Gene Ther 15 2008 526 534
91. N. Chattopadhyay, and A. Chatterjee Studies on the expression of alpha(v)beta3 integrin receptors in non-malignant and malignant human cervical tumor tissues J Exp Clin Cancer Res 20 2001 269 275
92. J. Kim, J.H. Kim, K.J. Choi, P.H. Kim, and C.O. Yun E1A- and E1B-double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects Hum Gene Ther 18 2007 773 786
93. I. Delgado-Enciso, D. Cervantes-Garcia, I.A. Martinez-Davila, R. Ortiz-Lopez, R. Alemany-Bonastre, and C.I. Silva-Platas A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms J Gene Med 9 2007 852 861
94. K. Fisher Striking out at disseminated metastases: the systemic delivery of oncolytic viruses Curr Opin Mol Ther 8 2006 301 313
95. G. Fulci, L. Breymann, D. Gianni, K. Kurozomi, S.S. Rhee, and J. Yu Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses Proc Natl Acad Sci USA 103 2006 12873 12878
96. A.T. Power, and J.C. Bell Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy Gene Ther 15 2008 772 779
97. C. Willmon, K. Harrington, T. Kottke, R. Prestwich, A. Melcher, and R. Vile Cell carriers for oncolytic viruses: Fed Ex for cancer therapy Mol Ther 17 2009 1667 1676
98. E.K. Mader, Y. Maeyama, Y. Lin, G.W. Butler, H.M. Russell, and E. Galanis Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model Clin Cancer Res 15 2009 7246 7255
99. S.C. Cheong, Y. Wang, J.H. Meng, R. Hill, K. Sweeney, and D. Kirn E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models Cancer Gene Ther 15 2008 40 50
100. M. Toda, S.D. Rabkin, H. Kojima, and R.L. Martuza Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity Hum Gene Ther 10 1999 385 393
101. M.H. Moehler, M. Zeidler, V. Wilsberg, J.J. Cornelis, T. Woelfel, and J. Rommelaere Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells Hum Gene Ther 16 2005 996 1005
102. L. Heinzerling, V. Kunzi, P.A. Oberholzer, T. Kundig, H. Naim, and R. Dummer Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells Blood 106 2005 2287 2294
103. T. Kottke, G. Hall, J. Pulido, R.M. Diaz, J. Thompson, and H. Chong Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice J Clin Invest 120 2010 1551 1560
104. J. Lacroix, B. Leuchs, J. Li, G. Hristov, H.E. Deubzer, and A.E. Kulozik Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells Int J Cancer 127 2010 1230 1239
105. F. Benencia, M.C. Courreges, N.W. Fraser, and G. Coukos Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation Cancer Biol Ther 7 2008 1194 1205
106. R. Liu, S. Varghese, and S.D. Rabkin Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice Cancer Res 65 2005 1532 1540
107. K. Ottolino-Perry, J.S. Diallo, B.D. Lichty, J.C. Bell, and J.A. McCart Intelligent design: combination therapy with oncolytic viruses Mol Ther 18 2010 251 263
108. D. Bonnet, and J.E. Dick Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Nat Med 3 1997 730 737
109. C.A. O'Brien, A. Pollett, S. Gallinger, and J.E. Dick A human colon cancer cell capable of initiating tumour growth in immunodeficient mice Nature 445 2007 106 110
110. L. Ricci-Vitiani, D.G. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, and C. Peschle Identification and expansion of human colon-cancer-initiating cells Nature 445 2007 111 115
111. M.E. Prince, R. Sivanandan, A. Kaczorowski, G.T. Wolf, M.J. Kaplan, and P. Dalerba Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma Proc Natl Acad Sci USA 104 2007 973 978
112. D. Dingli, and F. Michor Successful therapy must eradicate cancer stem cells Stem Cells 24 2006 2603 2610
113. M. Dean, T. Fojo, and S. Bates Tumour stem cells and drug resistance Nat Rev Cancer 5 2005 275 284
114. J.J. Short, and D.T. Curiel Oncolytic adenoviruses targeted to cancer stem cells Mol Cancer Ther 8 2009 2096 2102
115. T.P. Cripe, P.Y. Wang, P. Marcato, Y.Y. Mahller, and P.W. Lee Targeting cancer-initiating cells with oncolytic viruses Mol Ther 17 2009 1677 1682
116. -/low cells Mol Ther 15 2007 2088 2093
117. P. Marcato, C.A. Dean, C.A. Giacomantonio, and P.W. Lee Oncolytic reovirus effectively targets breast cancer stem cells Mol Ther 17 2009 972 979
118. S.A. Bapat Human ovarian cancer stem cells Reproduction 140 2010 33 41
119. R.C. Bast Jr., B. Hennessy, and G.B. Mills The biology of ovarian cancer: new opportunities for translation Nat Rev Cancer 9 2009 415 428
120. M. Zimmermann, S. Armeanu, I. Smirnow, S. Kupka, S. Wagner, and M. Wehrmann Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses Int J Oncol 34 2009 1247 1256
121. K. Geletneky, A.D. Hartkopf, R. Krempien, J. Rommelaere, and J.R. Schlehofer Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection J Biomed Biotechnol 2010 2010 350748
122. M. Raki, A. Kanerva, A. Ristimaki, R.A. Desmond, D.T. Chen, and T. Ranki Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer Gene Ther 12 2005 1198 1205
123. M. Raki, M. Sarkioja, R.A. Desmond, D.T. Chen, R. Butzow, and A. Hemminki Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer Gynecol Oncol 108 2008 166 172
124. A.R. Yoon, J.H. Kim, Y.S. Lee, H. Kim, J.Y. Yoo, and J.H. Sohn Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin Hum Gene Ther 17 2006 379 390
125. M. Takakura, M. Nakamura, S. Kyo, M. Hashimoto, N. Mori, and T. Ikoma Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination Cancer Gene Ther 17 2010 11 19
126. S.V. Blank, S.C. Rubin, G. Coukos, K.M. Amin, S.M. Albelda, and K.L. Molnar-Kimber Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation Hum Gene Ther 13 2002 627 639
127. J.A. McCart, M. Puhlmann, J. Lee, Y. Hu, S.K. Libutti, and H.R. Alexander Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression Gene Ther 7 2000 1217 1223
128. D. Dingli, K.W. Peng, M.E. Harvey, S. Vongpunsawad, E.R. Bergert, and R.A. Kyle Interaction of measles virus vectors with Auger electron emitting radioisotopes Biochem Biophys Res Commun 337 2005 22 29
129. D.R. Shafren, D. Sylvester, E.S. Johansson, I.G. Campbell, and R.D. Barry Oncolysis of human ovarian cancers by echovirus type 1 Int J Cancer 115 2005 320 328
130. R. Myers, S. Greiner, M. Harvey, D. Soeffker, M. Frenzke, and K. Abraham Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer Cancer Gene Ther 12 2005 593 599
131. Y. Unno, Y. Shino, F. Kondo, N. Igarashi, G. Wang, and R. Shimura Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain Clin Cancer Res 11 2005 4553 4560
132. G.J. Bauerschmitz, A. Kanerva, M. Wang, I. Herrmann, D.R. Shaw, and T.V. Strong Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer Int J Cancer 111 2004 303 309
133. C. Heise, I. Ganly, Y.T. Kim, A. Sampson-Johannes, R. Brown, and D. Kirn Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status Gene Ther 7 2000 1925 1929
134. Y. Tsuruta, L. Pereboeva, M. Breidenbach, D.T. Rein, M. Wang, and R.D. Alvarez A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer Clin Cancer Res 14 2008 3582 3588
135. K. Hamada, S. Kohno, M. Iwamoto, H. Yokota, M. Okada, and M. Tagawa Identification of the human IAI.3B promoter element and its use in the construction of a replication-selective adenovirus for ovarian cancer therapy Cancer Res 63 2003 2506 2512
136. A. Merron, P. Baril, P. Martin-Duque, A. de la Vieja, L. Tran, and A. Briat Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours Eur J Nucl Med Mol Imaging 37 2010 1377 1385